This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
JERSEY CITY, N.J., May 13, 2013 /PRNewswire/ -- Optimer Pharmaceuticals (NASDAQ: OPTR) (the "Company" or "Optimer") today announced the appointment of Mr. Eric Sirota as Chief Operating Officer. Mr. Sirota will be responsible for directing Optimer's corporate strategy with regard to DIFICID®.
"Eric has tremendous experience and has demonstrated leadership in building pharmaceutical brands in
the United States and abroad and has dedicated his career to making important new medicines available to the medical profession for the benefit of patients," said Dr.
Hank McKinnell, Chairman and CEO of Optimer. "His appointment fills a significant need at Optimer, and will allow me to focus more of my time on the strategic review process we announced in late February. Keeping the core business functioning well during this process is critical to Optimer and its stockholders, and Eric will be responsible for maintaining and growing our operations."
Mr. Sirota, 51 years old, operated a consultant practice in the healthcare industry for more than three years, consulting with numerous pharmaceutical companies and healthcare service organizations to develop new, and enhance existing, business opportunities with a focus on strategy, operational efficiency and organizational design. Mr. Sirota has served as a consultant to the Company since
March 8, 2013, providing product marketing and business advice to Optimer's Board of Directors and Dr. McKinnell. In addition, from
February 2010 until
December 2010, Mr. Sirota served as President of Commercial Services of inVentiv Health, Inc., a provider of clinical, commercial and consulting services to the healthcare industry, where he developed strategies to address the need for integrated analytic, sales and marketing solutions that enhance brand revenue, drive efficiency and lower costs. Prior to
June 2009, Mr. Sirota served as an executive of Pfizer Inc., most recently as Vice President of Pfizer's US Marketing, Commercial Strategy and Innovation and Regional Sales, responsible for the neuroscience and pain franchises. During his over twenty-year career at Pfizer, Mr. Sirota was responsible for 12 therapeutic areas and more than 25 brands, including anti-infectives. He received his B.S. degree in Pharmacy from
Rutgers College of Pharmacy and his Master of Business Administration degree from The Wharton School, The
University of Pennsylvania.
About Optimer Pharmaceuticals
We are a global biopharmaceutical company currently focused on commercializing our antibiotic product DIFICID® (fidaxomicin) tablets in
the United States and
Canada, and developing other fidaxomicin products in
the United States and worldwide, both by ourselves and with our partners and licensees. DIFICID, a macrolide antibacterial drug, was approved by the U.S. Food and Drug Administration on
May 27, 2011, for the treatment of
Clostridium difficile-associated diarrhea, or CDAD, in adults 18 years of age and older. Fidaxomicin has also received marketing authorization in other jurisdictions, including the European Union, where it is marketed under the trade name DIFICLIR™ by our licensee, Astellas Pharma Europe. CDAD is the most common symptom of
Clostridium difficile infection, or CDI. Additional information can be found at